Effect of lercanidipine on kidney microanatomy in Cohen-Rosenthal diabetic hypertensive rats.
The study was undertaken to determine the effect of treatment with the dihydropyridine-type calcium antagonist lercanidipine on the renal vasculature in Cohen-Rosenthal diabetic hypertensive rats, a genetic model of hypertension associated with type 2 diabetes mellitus. Eight animals were given a daily oral dose of 3 mg/kg lercanidipine in drinking water for 8 weeks, and 6 control animals received no treatment. The effects on blood pressure, glucose level, and kidney microanatomy were evaluated. Lercanidipine reduced systolic blood pressure and glucose level. In the control group small arteries and glomerular arterioles exhibited wall thickening and luminal narrowing. Lercanidipine administration prevented the changes in small-sized arteries and glomerular arterioles. The glomerular changes observed in the untreated Cohen-Rosenthal diabetic hypertensive rats were not seen in the lercanidipine-treated animals. Lercanidipine also had beneficial effects on the renal vasculature, suggesting that the compound may be considered for treating hypertension associated with diabetes.
Rosenthal
Talma
T
Department of Physiology and Pharmacology, Hypertension Research Unit, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. rtalma@post.tau.ac.il
Rosenmann
Eliezer
E
Tomassoni
Daniele
D
Amenta
Francesco
F
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001786:Blood Glucose; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D004095:Dihydropyridines / Q000494:pharmacology*; D004195:Disease Models, Animal; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000033:anatomy & histology / Q000098:blood supply* / Q000187:drug effects; D008297:Male; D051381:Rats; D012077:Renal Artery / Q000187:drug effects; D012079:Renal Circulation / Q000187:drug effects
D000959:Antihypertensive Agents; D001786:Blood Glucose; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; C060343:lercanidipine